Loading...

Sandip Patel

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Faculty Mentoring
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2020 Sep 30. Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807.
      View in: PubMed   Mentions: 1     Fields:    
    2. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2020 Sep 03. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280.
      View in: PubMed   Mentions:    Fields:    
    3. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020 08 18; 117(33):20159-20170. Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, Agrawal K, Gonzalez GM, Wang Y, Patel SP, Rana TM. PMID: 32747553.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    4. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget. 2020 Jul 14; 11(28):2740-2746. Yun K, Daniels G, Gold K, Mccowen K, Patel SP. PMID: 32733645.
      View in: PubMed   Mentions:    Fields:    
    5. Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Jpn J Clin Oncol. 2020 Jul 09; 50(7):800-809. Wallis CJD, Lawson K, Butaney M, Satkunasivam R, Parikh J, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. PMID: 32083295.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 May 15; 26(10):2434. Patel SP, Othus M, Chae YK, Kurzrock R. PMID: 32414761.
      View in: PubMed   Mentions:    Fields:    
    7. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020 03; 579(7800):567-574. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Knight R. PMID: 32214244.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    8. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 01; 26(11):2524-2534. Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL. PMID: 32144134.
      View in: PubMed   Mentions: 1     Fields:    
    9. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 03; 18(3):230-241. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. PMID: 32135517.
      View in: PubMed   Mentions: 3     Fields:    
    10. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Oncologist. 2020 Jul; 25(7):562-e1012. Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F. PMID: 32048771.
      View in: PubMed   Mentions: 1     Fields:    
    11. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Jun 01; 26(11):2546-2555. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. PMID: 32034076.
      View in: PubMed   Mentions: 1     Fields:    
    12. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 May 15; 26(10):2290-2296. Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. PMID: 31969335.
      View in: PubMed   Mentions: 9     Fields:    
    13. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 12; 17(12):1464-1472. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, Hughes M. PMID: 31805526.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    14. Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade. Oncology. 2020; 98(2):123-130. Galant-Swafford J, Troesch A, Tran L, Weaver A, Doherty TA, Patel SP. PMID: 31665718.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2019 09 15; 200(6):e31-e43. Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. PMID: 31518182.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. PMID: 31446141.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    17. GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. J Gen Intern Med. 2019 08; 34(8):1658-1661. Bordin-Wosk T, Patel SP, Horman SF. PMID: 31062226.
      View in: PubMed   Mentions:    Fields:    
    18. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Apr 01; 5(4):529-536. Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. PMID: 30605213.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    19. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    20. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 07; 16(7):807-821. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 30006423.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    21. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 10; 23(10):1236-1241. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. PMID: 29769383.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. J Palliat Med. 2018 05; 21(5):694-699. Wiesenthal AC, Patel SP, LeBlanc TW, Roeland EJ, Kamal AH. PMID: 29658821.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 03 15; 124(6):1288-1296. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. PMID: 29211306.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    24. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. . 2017 Dec; 16(12):2645-2655. Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ. PMID: 29203694.
      View in: PubMed   Mentions:
    25. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    26. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. . 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions:
    27. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    28. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    29. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017 03; 36(1):179-190. Khagi Y, Kurzrock R, Patel SP. PMID: 27873079.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    30. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    31. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391.
      View in: PubMed   Mentions:
    32. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemother Pharmacol. 2016 Sep; 78(3):577-84. Beg MS, Azad NS, Patel SP, Torrealba J, Mavroukakis S, Beatson MA, Wang XP, Arlen PM, Morse MA. PMID: 27449137.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    33. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. PMID: 27185373.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    34. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015 Jun; 64(6):677-88. Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. PMID: 25742933.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    36. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. . 2015 Apr; 14(4):847-56. Patel SP, Kurzrock R. PMID: 25695955.
      View in: PubMed   Mentions:
    37. Designing effective vaccines for colorectal cancer. Immunotherapy. 2014; 6(8):913-26. Patel SP, Osada T, Lyerly HK, Morse MA. PMID: 25313570.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    Sandip's Networks
    Concepts (148)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (49)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑